Skip to content

Public FDA record

Z-1267-2021: VITROS SARS-CoV-2 Antigen Reagent Pack - The VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Reagent

Recall record Z-1267-2021 for Ortho-Clinical Diagnostics, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1267-2021
Company in FDA record
Ortho-Clinical Diagnostics, Inc.
FDA record creation date
Mar 17, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

VITROS Immunodiagnostic Products SARS-CoV-2 Antigen False Reactive Results Associated When Using Remel M4RT Viral Transport Media

Source facts

Action
Ortho Clinical issued Urgent Product Correction Notification letter on 12 February 2021 (CL2021-064) stated reason , health risk and action to take: Ortho is collaborating with the manufacturer of Remel M4RT VTM to identify the root cause of the issue. " Ortho no longer recommends use of Remel M4RT VTM with the VITROS SARS-CoV-2 Antigen assay. " The VITROS SARS-CoV-2 Antigen Instructions for Use has been updated to remove Remel M4RT VTM from the Intended Use and to also add WHO formulation, Bartels FlexTrans and saline. The revised assay IFU is located on our website: https://www.orthoclinicaldiagnostics.com. Our website is the official source of information for all VITROS Products. Refer to the Revision History section included at the end of each IFU for a comprehensive list of changes. Technical changes in each IFU are marked by a change bar (|) to the left of the edited text. Discontinue use of Remel M4RT VTM and transition to an alternate media. " As your facility transitions to an alternate transport media, Ortho advises that your facility confirm the performance of each new lot of Remel M4RT VTM by doing the following: o Test each lot of Remel M4RT VTM with no specimen added, with and without the addition of extraction buffer. Suitable lots of Remel M4RT VTM will produce S/C values consistent with the values observed for the VITROS SARS-CoV-2 Antigen Control 1. o If possible, confirm the first 5 samples that produce reactive results on the VITROS SARS-CoV-2 Antigen assay using polymerase chain reaction (PCR) methodology, for each new lot of Remel M4RT VTM. " Post this notification by each system that processes the VITROS SARS-CoV-2 Antigen assay. " Complete the enclosed Confirmation of Receipt form no later than February 22, 2021. " Please forward this notification if the product was distributed outside of your facility.
Initiated
2021-02-12
Root cause
Under Investigation by firm
Terminated
2022-01-24
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Australia, Belgium, Canada L3R 4G5, Chile, Colombia, Denmark, France, Germany, India, Italy, Japan, Portugal, Russia, Singapore 609917, Spain, United Kingdom.
Recall number
Z-1267-2021
Recall status
Terminated
CDRH record ID
185884
FDA record created
2021-03-17
Recall event number
87356

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗